louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00664508: Mobility Assessment of Patients With Total Hip Arthroplasty
Official title: Mobility Assessment of Patients With Total Hip Arthroplasty: Joint Mechanics and Rehabilitation
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Osteoarthritis
Arthroplasty
Hip Replacement
Keywords: Arthroplasty
Hip Replacement
motion analysis
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2008-04-23
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Comparative study with a control group
Primary purpose: OTHER

Brief summary: The purpose of this study is to describe the 3D joint biomechanics of the lower extremities of patients having had a total hip replacement or hip resurfacing surgery as compared to a healthy age and weight matched control group during level walking, stair ascent and descent, and entering and exiting the front seat of a car.

Detailed description: Much research has shown that patients are generally satisfied with pain relief in the months and years following a total hip replacement (THR) or hip resurfacing procedure. However, many express dissatisfaction with their ability to perform daily activities, a reduced walking ability and long-term lower extremity muscle weakness. Given the general lack of knowledge surrounding joint motion of the lower extremities in the THR population, there is a need to characterize the joint mechanics of people having undergone THR, so that interventions and rehabilitation strategies can be designed to reduce post-operative complications and improve mobility.

Eligibility criteria: Inclusion Criteria:

* 15 patients between the ages of 50 and 75 yrs having undergone a primary total hip replacement or hip resurfacing within 6 to 18 months of the study will participate, as well as an equal number of age, sex, height and weight matched healthy control participants.

Exclusion Criteria:

* Potential participants for the control group will be asked if they have had previous lower limb ailments or surgery, and if they have they will be excluded. Moreover, the THR participants cannot have had secondary hip replacement due to infection, revision surgery, or a concomitant surgical procedure (i.e., graft). Participants from both groups cannot have had any medical conditions which could affect physical movement such as a stroke.

Primary outcomes:
measure: Joint mechanics of people having undergone total hip replacement
timeFrame: 6-18 months post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: OHRI
state: Ontario
Study officials:
affiliation: University of Ottawa / The Ottawa Hospital
name: Paul E Beaule, MD, FRCSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01230008: Radiotherapy in Primary Mediastinal Lymphoma
Official title: Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adjuvant Radiotherapy on Complete Remission Patients
Keywords: primary mediastinal lymphoma
radiotherapy
chemotherapy
rituximab
Lead sponsor: Instituto Mexicano del Seguro Social
Sponsor class: OTHER_GOV
First posted: 2010-10-28
Enrollment: 198
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with primary mediastinal lymphoma treated in an tertiary medical center

Brief summary: The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP


Eligibility criteria: Inclusion Criteria:

Diagnosis of primary mediastinal lymphoma No previous treatment performance status \< 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function

Exclusion Criteria:

pregnancy

-

Primary outcomes:
measure: measurement of progression free-survival and overall survival at > 5 years
timeFrame: 5 years
Secondary outcomes:
measure: assess toxicity secondary to mediastinal radiotherapy
timeFrame: > 5 years
Other outcomes:
Locations:
city: Mèxico DF
country: Mexico
facility: Oncology Research Unit
state: DF
Study officials:
References:
Clinical trial NCT04521023: A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
Official title: A Randomized, Double-blind, Non-inferiority, Multi-center, Phase 4 Trial to Evaluate the Blood Pressure Lowering Effect of a Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Lead sponsor: Chong Kun Dang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2020-08-20
Enrollment: 132
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients


Eligibility criteria: Inclusion Criteria:

* over 19 years old
* Agreement with written informed consent
* Hypertensive Patients

Exclusion Criteria:

* Patients with secondary hypertension
* Participated in other trial within 30 days
* In investigator's judgement

Primary outcomes:
measure: cSBP(central Systolic Blood Pressure)
timeFrame: change after 8 weeks compared to baseline
Secondary outcomes:
measure: cDBP(central Diastolic Blood Pressure)
timeFrame: change after 8 weeks compared to baseline
measure: sitSBP(sitting Systolic Blood Pressure)
timeFrame: change after 8 weeks compared to baseline
measure: sitDBP(sitting Diastolic Blood Pressure)
timeFrame: change after 8 weeks compared to baseline
Other outcomes:
Locations:
city: Suwon
country: Korea, Republic of
facility: Ajou University Hospital
state: Gyeonggi-do
city: Anyang
country: Korea, Republic of
facility: Hallym Univ. Medical Center
city: Daegu
country: Korea, Republic of
facility: Daegu Catholic Univ. Medical Center
city: Goyang-si
country: Korea, Republic of
facility: MYONGJI Hospital
city: Ilsan-gu
country: Korea, Republic of
facility: Inje University Ilsan Paik Hospital
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
city: Jeju
country: Korea, Republic of
facility: Jeju National University Hospital
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Hallym University Kangnam Sacred Heart Hospital
city: Seoul
country: Korea, Republic of
facility: Hanyang University Medical Center
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: SNU Boramae Medical Center
city: Ulsan
country: Korea, Republic of
facility: Ulsan University Hospital
city: Wŏnju
country: Korea, Republic of
facility: Wonju Severance Christian Hospital
Study officials:
References:
Clinical trial NCT05269823: Topical Ice-therapy for Intravitreal Injections
Official title: Topical Ice-therapy for Pain Modulation During Intravitreal Injections: A Prospective Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Anesthesia; Hypothermia
Injection Site Irritation
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2022-03-08
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Purpose: To examine the difference in patient's pain experience in the setting of intravitreal anti-VEGF injections with pretreatment of topical ice-therapy compared with no-ice.


Eligibility criteria: Inclusion Criteria:

* All patients aged 18 or older evaluated by a single retina specialist at the University of Minnesota Department of Ophthalmology with a clinical indication necessitating an anti-VEGF intravitreal injection

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Discomfort assessed by the visual analog scale
timeFrame: This will be assessed at five minutes after the conclusion of the intravitreal injection
measure: Itching assessed by the visual analog scale
timeFrame: This will be assessed at five minutes after the conclusion of the intravitreal injection
measure: Burning assessed by the visual analog scale
timeFrame: This will be assessed at five minutes after the conclusion of the intravitreal injection
measure: Overall Pain assessed by the visual analog scale
timeFrame: This will be assessed at five minutes after the conclusion of the intravitreal injection
measure: Overall Tolerability assessed by the visual analog scale
timeFrame: This will be assessed at five minutes after the conclusion of the intravitreal injection
Secondary outcomes:
measure: Discomfort assessed by the visual analog scale
timeFrame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
measure: Itching assessed by the visual analog scale
timeFrame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
measure: Burning assessed by the visual analog scale
timeFrame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
measure: Overall Pain assessed by the visual analog scale
timeFrame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
measure: Overall Tolerability assessed by the visual analog scale
timeFrame: This will be assessed at 24-hours after the conclusion of the intravitreal injection
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Jade Moon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01620723: Evaluation of Breastfeeding Support After Short Time Hospitalization
Official title: Effect Evaluation of a Theory and Evidence Based Programme for Establishing Effective Breastfeeding After Short Time Hospitalization Post Partum
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breastfeeding
Keywords: Breastfeeding
Breastfeeding self efficacy
Lead sponsor: Danish Committee for Health Education
Sponsor class: OTHER
Collaborators: name: TrygFonden, Denmark
First posted: 2012-06-15
Enrollment: 3541
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate if the developed theory and evidence based programme has a positive effect on mother's breastfeeding self efficacy, establishing an effective breastfeeding and breastfeeding duration after short time hospitalization.


Eligibility criteria: Inclusion Criteria:

* pregnant women (gestational week 35-36)

Exclusion Criteria:

* women with known physical, psychological and/or social illness/problem that result in hospitalization more than 50 hours after delivery
* women with known pregnancy related illness that result in hospitalization more than 50 hours after delivery
* Women not understanding or speaking Danish
* women expecting multiple babies
* women having decided not to breastfeed
* women expecting to deliver at another hospital than the one she has been visiting during pregnancy

Primary outcomes:
measure: Parents breastfeeding self efficacy
timeFrame: 7 days post partum
Secondary outcomes:
measure: Effective breastfeeding
timeFrame: 7 days post partum
measure: Duration of exclusive and full breastfeeding
timeFrame: 7 and 30 days post partum and 6 month post partum
measure: Baby's morbidity
timeFrame: 7 and 30 days post partum and 6 month post partum
measure: Breastfeeding problems
timeFrame: 7 and 30days and 6 month post partum
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg Sygehus
city: Hjoerring
country: Denmark
facility: Sygehus Vendsyssel
city: Horsens
country: Denmark
facility: Horsens sygehus
city: Kolding
country: Denmark
facility: Kolding Sygehus
city: Nykøbing F
country: Denmark
facility: Nykøbing F Sygehuse
city: Randers
country: Denmark
facility: Regionshospitalet Randers
city: Sønderborg
country: Denmark
facility: Haderslev/Sønderborg sygehus
city: Thisted
country: Denmark
facility: Sygehus Thy-Mors
city: Viborg
country: Denmark
facility: Regionshospitalet Viborg
Study officials:
affiliation: Danish Committee for Health Education
name: Ingrid Nilsson, RN, MSA, IBCLC
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yonemoto N, Nagai S, Mori R. Schedules for home visits in the early postpartum period. Cochrane Database Syst Rev. 2021 Jul 21;7(7):CD009326. doi: 10.1002/14651858.CD009326.pub4.
Clinical trial NCT00442923: "The Evaluation of Stimulant Withdrawal"
Official title: Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Anxiety
Relapse
Substance Addiction
Keywords: Methamphetamine
Coreg
Withdrawal
anxiety
Substance Addiction
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2007-03-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.


Eligibility criteria: Inclusion Criteria:

* Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
* Must meet the clinical definition for methamphetamine dependence
* Self-reported methamphetamine use within 10 days of entering the study
* Must be able to understand and sign the consent form

Exclusion Criteria:

* Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
* Pregnant or nursing mothers
* Psychosis
* Dementia
* Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
* History of withdrawal seizures or delirium tremors
* Use of MAO inhibitors within the last two weeks
* Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: US Veterans Hospital
state: Oregon
Study officials:
affiliation: OHSU/ US VA
name: Paul S Berger, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00238823: Cryoablation Versus Radiofrequency Ablation
Official title: A Review and Comparison of Cryoablation and Radiofrequency Ablation in Children
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Congenital Disorders
Keywords: cryoablation
radiofrequency ablation
pediatrics
cardiology
Lead sponsor: Children's Healthcare of Atlanta
Sponsor class: OTHER
First posted: 2005-10-14
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: The purpose of this retrospective study is to describe why and when we used cryo and why we crossed over when we used both RFA and cryo. It is also to determine if there is some predictor that would make us say one patient would be better served with one technique than another and to describe our overall acute success rate and then our 6-month recurrence rate with cryo ablation and compare it to our known success rate with RFA.

Detailed description: Cryotherapy (Cryo) is a new ablation energy source used instead of the radiofrequency (RFA) method for ablation of septal pathways. In the past year, we have used cryo approximately 50 times, however 50% of the cryo procedures crossed over from RFA to cryo or cryo to RFA. It appears to me that cryo use should be as an adjunct therapy to RFA instead of replacement of RFA.

I would like to describe why and when we used cryo and why we crossed over when we used both RFA and cryo. I would like to determine if there is some predictor that would make us say one patient would be better served with one technique than another. I would also describe our overall acute success rate and then our 6-month recurrence rate with cryo ablation and compare it to our known success rate with RFA. All of this can be done with a chart review.

This will be done through a retrospective study.

Eligibility criteria: Inclusion Criteria:

* charts between January 1 and 2004 to December 31, 2004
* pediatric population
* those who were ablated

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Children's Healthcare of Atlanta
state: Georgia
Study officials:
affiliation: Sibley Heart Center
name: Margaret Strieper, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03587623: Copeptin Serum Level in Liver Transplant Recipients
Official title: Copeptin Serum Level in Liver Transplant Recipients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Cirrhosis
Copeptin
Liver Transplant
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
First posted: 2018-07-16
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing liver transplant

Brief summary: The study aim is to measure perioperative copeptin concentration in blood of liver transplant recipients and to assess whether there is a correlation between its level and hemodynamic derangement.


Eligibility criteria: Inclusion Criteria:

- Patient undergoing liver transplantation

Exclusion Criteria:

* Serum creatinine \> 1,5 mg/dl
* Retransplantation
* Patient refusal
* CRRT or dialysis preoperatively

Primary outcomes:
measure: Serum Copeptin concentration
timeFrame: Baseline, intraoperatively, 1,3,7,21 day postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: I Klinika Anestezjologii WUM
state: Mazovian Voivodeship
Study officials:
References:
Clinical trial NCT00843323: Photodynamic Therapy (PDT) Effect on Large Surface Photodamaged Skin
Official title: Histological and Immunohistochemical Study of Photodamaged Skin Submitted to MAL-PDT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Actinic Keratosis
Photoaging
Solar Elastosis
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: University of Regensburg
First posted: 2009-02-13
Enrollment: 26
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study, 26 patients were selected and included for full-face photodynamic therapy sessions. All patients presented signs of photoaging skin and multiple actinic keratosis. Photographs and Biopsies were taken before and after the procedure. Clinical and histological aspects as well as immunohistochemical aspects regarding neocollagen induction and tumor expression were evaluated.

Detailed description: Study design:

Patients and methods:

26 patients (16 females, 8 males) age 35-90 years, mean 59,4 y Skin types I-IV, severely photodamaged facial skin Multiples Aks on the face ( total 268) minimum of 3 per patient Approved by local ethical committee and informed consent given

Treatment procedure:

Prior curettage Full-face MAL application ( Metvix ®, Galderma France) 1,5 tube per treatment Incubation time 3 hs - in the first treatment session; and 1,5 h - in the 2 nd and 3 rd sessions Illumination LED (Aktilite® Photocure, Norway) 635 nm 37 J/cm2 3 treatments performed, one month apart Pain monitoring: forced air cooling device

Evaluation:

Clinical - 5 point scale based on Dover's and Zane's studies Dover JS et al. Topical ALA combined with IPL in photoaging. Arch Dermatol 2005; 141: 1247-52 Zane et al. Clinical and echographical analysis of MAL- PDT in photodamaged skin. Laser Surg Med 2007; 39: 203-9

Histological - Hematoxilin- Eosin staining

Immunohistochemical study- HP 53, Metalloproteinases, Procollagen I,

Eligibility criteria: Inclusion Criteria:

* Patients with severe photodamage and at least 3 actinic keratosis on the face

Exclusion Criteria:

* Pregnancy, laser, chemical peel, imiquimod or 5-Fu treatment in the last year

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hospital das Clinicas - Faculdade de Medicina USP - Sao Paulo- Brazil
name: Luis A Torezan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01559623: Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overactive Bladder Syndrome
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2012-03-21
Enrollment: 766
Sex: FEMALE
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: clinic for urogynecology

Brief summary: The purpose of this study is to assess the prevalence of mycoplasma hominis, ureaplasma urealyticum, neisseria gonorrhea, and chlamydia trachomatis in women with overactive bladder symptoms, and to correlate these findings with cystoscopic and urodynamic findings.


Eligibility criteria: Inclusion criteria:

* women with urogynecologic and urodynamic examination at our institution between 1.1.2009 and 31.12.2011

Exclusion criteria:

* none

Primary outcomes:
measure: prevalence of ureaplasma urealyticum
timeFrame: time of urogynecologic assessment
measure: prevalence of mycoplasma hominis
timeFrame: time of urogynecologic assessment
measure: prevalence of neisseria gonorrhea
timeFrame: time of urogynecologic assessment
measure: prevalence of chlamydia trachomatis
timeFrame: time of urogynecologic assessment
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Gynecology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Division of Gynecology
name: David Amos Scheiner, MD
role: PRINCIPAL_INVESTIGATOR
References: